[Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
Many retinal vascular diseases have all been shown to share the upregulation of VEGF expression of vascular endothelial growth factor (VEGF) in the pathologies, recent clinical trials regarding the intravitreal injection of anti-VEGF agents have shown a shrink of CNV and decreased leakage. Certain efficacy was shown in the treatment of angiogenic pathologies including neovascular AMD, choroidal neovascularization caused by several different causes, macular edema by diabetic retinopathy and vein occlusion, Retinopathy of prematurity, and neovascular glaucoma. A controversies in the indication of treatment using anti-VEGF are: inhibit the new vessels of proliferative diabetic retinopathy? decreased bleeding using intravitreal bevacizumab before vitrectomy of diabetic retinopathy? reduced leaking in Coats Diseases? The controversy based on a new finding of fibrosis formation after using intravitreal anti-VEGF. however, recurrent/persistent leaking from CNV or macular edema is common, there is a potential risk of endophthalmitis for frequently intravitreal injections.